Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment

Control of <i>Mycobacterium tuberculosis</i> infection continues to be an issue, particularly in countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The effort to reduce the catastrophic cost of TB with the WHO's End TB Strategy in 2035 is still...

Full description

Saved in:
Bibliographic Details
Main Authors: Filia Stephanie (Author), Mutiara Saragih (Author), Usman Sumo Friend Tambunan (Author)
Format: Book
Published: MDPI AG, 2021-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_7bb350a2c56640cd92cf47bca8fe5f3d
042 |a dc 
100 1 0 |a Filia Stephanie  |e author 
700 1 0 |a Mutiara Saragih  |e author 
700 1 0 |a Usman Sumo Friend Tambunan  |e author 
245 0 0 |a Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment 
260 |b MDPI AG,   |c 2021-04-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics13050592 
500 |a 1999-4923 
520 |a Control of <i>Mycobacterium tuberculosis</i> infection continues to be an issue, particularly in countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The effort to reduce the catastrophic cost of TB with the WHO's End TB Strategy in 2035 is still obstructed by the emergence of drug-resistant TB (DR-TB) cases as result of various mutations of the MTB strain. In the approach to combat DR-TB, several potential antitubercular agents were discovered as inhibitors for various existing and novel targets. Host-directed therapy and immunotherapy also gained attention as the drug-susceptibility level of the pathogen can be reduced due to the pathogen's evolutionary dynamics. This review is focused on the current progress and challenges in DR-TB treatment. We briefly summarized antitubercular compounds that are under development and trials for both DR-TB drug candidates and host-directed therapy. We also highlighted several problems in DR-TB diagnosis, the treatment regimen, and drug discovery that have an impact on treatment adherence and treatment failure. 
546 |a EN 
690 |a tuberculosis 
690 |a drug-resistance 
690 |a drug discovery and development 
690 |a host-directed therapy 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 13, Iss 5, p 592 (2021) 
787 0 |n https://www.mdpi.com/1999-4923/13/5/592 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/7bb350a2c56640cd92cf47bca8fe5f3d  |z Connect to this object online.